Division of Pulmonary and Critical Care, Department of Internal Medicine, University of Iowa, Iowa City, Iowa, USA.
Curr Opin Pulm Med. 2019 Sep;25(5):526-532. doi: 10.1097/MCP.0000000000000607.
Sarcoidosis is a multisystemic granulomatous disease, which commonly affects the lung. The natural course of the disease and prognosis are variable from asymptomatic, spontaneous remission to progressive disease, which requires treatment. Once treatment is initiated, tapering therapy can be problematic.
Corticosteroids are recommended as first-line therapy, but optimal regimen and duration of treatment is not well established. Treatment may differ based on severity of disease, extrapulmonary involvement, physician and patient preferences. We reviewed currently recommended regimens, particularly, in pulmonary sarcoidosis and the use of alternative treatments as corticosteroid-sparing agents.
Corticosteroid use is quite effective as initial therapy but is associated with significant side effects. An approach to tapering sarcoidosis therapy is not standardized, given the lack of evidence-based data. This review provides guidance based on the current literature.
结节病是一种多系统肉芽肿性疾病,常累及肺部。疾病的自然病程和预后各不相同,从无症状、自发缓解到需要治疗的进行性疾病。一旦开始治疗,逐渐减少治疗就会成为问题。
皮质类固醇被推荐作为一线治疗药物,但最佳方案和治疗持续时间尚未确定。治疗可能因疾病严重程度、肺外受累、医生和患者的偏好而异。我们综述了目前推荐的方案,特别是在肺结节病中以及使用替代治疗作为皮质类固醇保留剂。
皮质类固醇作为初始治疗非常有效,但也存在显著的副作用。由于缺乏基于证据的数据,逐渐减少结节病治疗的方法尚未标准化。本综述根据现有文献提供了指导。